The purpose of this study is to find out if antiretroviral drugs are safe and well tolerated by HIV-positive pregnant women and their infants in South Africa and Zambia.
Although the use of HAART in pregnancy has significantly reduced rates of vertical transmission of HIV-1, some questions remain regarding the safety of these therapies and their potential impact on the uninfected infant. The overall goal of the project is to establish a voluntary exposure-registry and perform observational surveillance on HIV - positive pregnant women who are exposed to antiretroviral products during the prenatal period, in order to evaluate the outcome of the pregnancy and safety of the products in HIV-positive pregnant women, and their infants.
Study Type
OBSERVATIONAL
Enrollment
600
University of Limpopo / Elizabeth Glaser Pediatric AIDS Foundation
Medunsa, South Africa
Center for Infectious Disease Research in Zambia (CIDRZ)
Lusaka, Zambia
Number of Congenital birth defects
Number of congenital birth defects among infants born in the study
Time frame: At birth
Adverse Pregnancy outcomes
Pregnancy outcomes other than normal live birth such as preterm birth, stillbirth and low birth weight
Time frame: At outcome of pregnancy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.